Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2005

View Archived Issues

PTC-124 begins phase II study for cystic fibrosis with FDA funding

Study to compare Xyotax and paclitaxel in women with advanced NSCLC

Exelixis and Bristol-Myers Squibb collaborate on LXR-targeting therapies

First milestone in Evotec and Takeda's Alzheimer's collaboration

Cephalon to acquire Zeneus Holdings

CA4P to be studied in combination with Avastin

BioDiem to study BDM-E in patients with diabetic macula edema

Inamed receives irrevocable offer and merger agreement from Allergan

First clinical trial of L-annamycin in relapsed and refractory ALL

PRTX-100 tested for first time in humans

Novelos to advance NOV-002 into pivotal phase III study for advanced NSCLC

Borean Pharma establishes proof-of-concept for TNF-alpha antagonist

New ROCK inhibitor displays antiangiogenic and antitumor effects

PK and tolerability profile of darunavir/low-dose ritonavir in humans

MK-0518: An effective short-term therapy in HIV-1 patients

Breast cancer responses not increased with tipifarnib-letrozole combination

ZK-EPO active in human breast cancer models

Scutellaria barbata extract (BZL-101) evaluated in phase I breast cancer trial

TAS-108 active, with acceptable toxicity, in postmenopausal breast cancer patients

Targeting Mcl-1 for leukemia

Xyrem launched in Germany for cataplexy in adult with narcolepsy

NDA filed for NRP-104 in ADHD

New analgesic agents reported in patent literature

Companies patent novel agents for gastrointestinal disorders

New agents reported with potential in treatment of Parkinson's disease and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...